Ferric Ammonium Citrate: A Comprehensive Reference
1. Identity, Chemical Characterization, and Physical Forms
1.1 Names and Identifiers
Ferric ammonium citrate (also widely known as ammonium ferric citrate or iron(III) ammonium citrate) is a coordination salt of trivalent iron, ammonia, and citric acid. It has the general formula [NH4]y[Fex(C6H4O7)]. The iron in the compound is trivalent (Fe3+). Common synonyms include ammonium iron(III) citrate, ferric ammonium citrate brown, ferric ammonium citrate green, ammoniacal ferrous citrate, and iron(III) ammonium citrate. It carries the food additive designation E381 in the European system and INS number 381 in the international numbering system. Its principal CAS numbers are 1185-57-5 (brown form) and, depending on stoichiometry, related variants; the EC number is 214-686-6.
1.2 Chemical Structure and Composition
All three carboxyl groups and the central hydroxyl group of citric acid are deprotonated in this compound. Research published in the European Journal of Inorganic Chemistry (2015) clarified the structural ambiguity that had persisted for over a century: although ferric ammonium citrate is administered to humans in drugs or food supplements, its exact composition and structural features had not been definitively known; that study reported that the major component in commercial FAC-brown and FAC-green is a trinuclear ferric citrate complex, namely [Fe3(cit)4H]6–. This complex comprises a dinuclear subunit in which two ferric ions with a 3.122(1) Å separation are bridged by two alkoxido oxygen atoms from two citrate ligands.
Iron ammonium citrate comprises iron(III) (Fe3+) and citrate ions (C6H5O73−) complexed together, where the ferric ion acts as the core metal ion creating numerous coordination bonds with the citrate ligand. The citrate ions act as a chelating agent, which helps prevent iron from forming insoluble precipitates or interacting with other compounds that could affect its stability or bioavailability.
1.3 Two Distinct Commercial Forms
The compound is commercially produced in two principal forms distinguished by stoichiometry and physical appearance:
- Brown (reddish-brown) form (CAS No. 1332-98-5): a complex salt of undetermined exact structure composed of 16.5 to 18.5% iron, approximately 9% ammonia, and 65% citric acid; it occurs as reddish-brown or garnet-red scales or granules, or as a brownish-yellowish powder.
- Green form (CAS No. 1333-00-2): a complex salt of undetermined exact structure composed of 14.5 to 16% iron, approximately 7.5% ammonia, and 75% citric acid; it occurs as thin transparent green scales, granules, a powder, or transparent green crystals.
The green type is more readily reduced by light than the brown. In bulk form, ferric ammonium citrate appears as a yellowish-brown to red solid with a faint odor of ammonia and is soluble in water.
1.4 Synthesis
Ferric ammonium citrate can be prepared by treating Fe(OH)3 with citric acid and ammonium hydroxide (NH4OH) in various ratios. The ratio of reactants determines which form — brown or green — is produced. A distinguishing feature of the compound is that it is very soluble in water, in contrast to ferric citrate, which is not very soluble.
1.5 Regulatory Status as a Food Additive
Ammonium ferric citrate is a food additive with E number E381 used as an acidity regulator. It is listed in the FAO/WHO Global Standard for Food Additives (GSFA) under additive number 381. As a food ingredient, it has an INS number of 381 and is used as an acidity regulator. It is also used in the pharmaceutical and food industries as an anticaking agent, acidity regulator, and nutritional supplement.
2. Historical and Traditional Use
2.1 Nineteenth-Century Medicinal Use
Few compounds have left such a vivid imprint on both art and industry as ferric ammonium citrate. Its story begins in the 19th century, a time of scientific curiosity and artistic experimentation. Since the 19th century, it has been utilized as a readily absorbable source of iron in tonics and elixirs to combat anemia and related conditions. Its high water solubility made it a preferred iron compound for liquid pharmaceutical preparations at a time when inorganic iron salts were poorly tolerated or difficult to formulate.
Ferric ammonium citrate (FAC) has been used extensively in medicine to treat iron-deficiency anemia in humans (including as an ingredient in the well-known tonic Geritol®) and animals. The brown form of FAC was historically the pharmaceutical-grade preparation used as a hematinic — a drug or supplement intended to increase hemoglobin — administered in liquid syrups, drops, and elixirs. The brown product has been used as a hematinic drug for the treatment of iron deficiency anemia and can be used as a food additive.
2.2 The Cyanotype Process and Blueprint History
Beyond its medicinal uses, ferric ammonium citrate played a foundational role in 19th-century photographic science. In 1842, English mathematician, astronomer, chemist, and experimental photographer Sir John Herschel invented the cyanotype — a photographic process resulting in a cyan-blue print. The photosensitive compound, a solution of ferric ammonium citrate and potassium ferricyanide, is coated onto paper. Areas of the compound exposed to strong light are converted to insoluble blue ferric ferrocyanide (Prussian blue). The soluble chemicals are washed off with water, leaving a light-stable print.
Herschel's innovation was to use ammonium iron(III) citrate or tartrate — then commercially available as an iron tonic and introduced to him by Alfred Smee — for photographic purposes. This detail is historically significant: the compound's availability as a pharmaceutical iron tonic was a direct precursor to its adaptation in photography. Cyanotypes were not widely used until 1880, when they became popular because they required only water for fixing the image. The process was eminently suited to its traditional role in reproducing technical drawings, its most common use in engineering and architecture until the advent of modern photocopiers.
While Herschel developed the process, it was Anna Atkins — an English botanist often celebrated as the first female photographer — who popularized cyanotype by using it to create detailed photographic records of plant specimens. Her 1843 book, Photographs of British Algae: Cyanotype Impressions, is considered the first book illustrated with photographic images.
2.3 Early Food Fortification Practices
Ferric ammonium citrate's history in nutritional applications dates back to the 19th century, when it was incorporated into tonics and elixirs to combat anemia and related conditions. Its introduction into processed foods as an iron fortifier came in the 20th century, as global awareness of iron-deficiency anemia grew. Ferric ammonium citrate is one of the few soluble iron compounds that can be added to dairy products without inducing off-flavors. This property made it particularly valuable for fortifying milk-based products, flour, and infant formulas. Most notably, it has been used in the Scottish beverage Irn-Bru.
3. Key Constituents and Active Components
3.1 Iron (Fe3+) as the Primary Active Constituent
The pharmacologically and nutritionally active component of ferric ammonium citrate is its trivalent iron (ferric, Fe3+) content. The brown form contains approximately 9% NH3, 16.5–18.5% Fe, and 65% hydrated citric acid; the green form contains approximately 7.5% NH3, 14.5–16% Fe, and 75% hydrated citric acid. Iron is an essential trace mineral required for the synthesis of hemoglobin, myoglobin, and numerous iron-containing enzymes, and is the central biological rationale for the compound's use.
3.2 The Role of Citrate
The citrate moiety is not merely a carrier but plays an important functional role in solubility and absorption. Some studies have found that iron from ferric ammonium citrate is much better absorbed when consumed at relatively low pharmacological doses, and that citric acid can increase iron absorption up to two to three times when present at quantities as high as 1 gram. Accordingly, the citrate in ferric ammonium citrate may make some enhancement in the absorbability of the ferric iron, with consequent improvements in haematological parameters.
From a structural chemistry standpoint, ferric citrate coordination complexes inhibit ferric iron precipitation, thereby increasing the pool of soluble ferric iron available for iron absorption. Ferric citrate complexes are soluble over a broad pH range, forming oligomeric complexes in low pH conditions and mononuclear complexes in higher pH conditions. The ability to form mononuclear complexes at higher pH likely enhances ferric ion absorption in the alkaline milieu of the duodenum.
3.3 Ammonium
The ammonium (NH4+) component serves as a counterion that enhances the overall solubility of the complex in water. The deprotonated hydroxyl group and two of the carboxylate groups ligate to the ferric center, while the third carboxylate group coordinates with the ammonium. The ammonium content is low in absolute terms (approximately 7.5–9%) and does not contribute meaningfully to nitrogen intake at supplemental doses.
4. Mechanism of Action
4.1 Intestinal Absorption of Non-Heme Ferric Iron
Ferric ammonium citrate delivers iron in the Fe3+ (ferric) oxidation state, which follows the non-heme iron absorption pathway. As most non-heme iron in the diet is in the ferric form, it first needs to be reduced to Fe2+ before it can be absorbed; this can be achieved by the actions of the membrane-bound ferric reductase duodenal cytochrome B (DCYTB or CYBRD1), which is expressed on the apical brush border membrane of intestinal epithelial cells. Ferrous iron is then transported across the apical membrane of enterocytes by the divalent metal transporter 1 (DMT1).
Ferrous iron is transported out of the cell via ferroportin and then oxidized to its ferric form by the copper-dependent transmembrane ferroxidase hephaestin (HEPH). In the circulatory system, iron is transported in its ferric form by transferrin.
4.2 Ferroportin Dependence
Research using murine models has helped elucidate the mechanisms by which ferric citrate-delivered iron is absorbed. Ferric citrate-delivered iron is enterally absorbed, but the specific mechanisms involved had not been evaluated, including the possibilities of conventional, transcellular ferroportin-mediated absorption and/or citrate-mediated paracellular absorption. Studies demonstrated efficacy of ferric citrate in high-hepcidin models, including TMPRSS6 knockout mice characterized by iron-refractory iron deficiency anemia. These animal data indicate that at least part of ferric citrate's iron absorption involves conventional ferroportin-mediated transport, although this is preliminary (animal model) evidence.
4.3 Hepcidin Regulation
The peptide hormone hepcidin is the master regulator of systemic iron homeostasis. Hepcidin promotes the internalization and degradation of ferroportin. Studies examining ferric ammonium citrate supplementation in children found that hepcidin levels increased after four weeks of iron supplementation treatment, consistent with the expected homeostatic response to rising iron stores. This hepcidin rise acts as a brake on further iron absorption, a mechanism relevant to understanding both the efficacy ceiling and the safety profile of FAC supplementation.
4.4 Limitation: Insoluble Ferric Hydroxide Formation
A key limitation on the bioavailability of FAC is the tendency of ferric iron to precipitate under certain pH conditions. The formation of unabsorbable insoluble ferric hydroxides in the duodenum is the reason why the absorption of ferric ammonium citrate (FAC) is usually significantly lower than that of ferrous salts. The citrate moiety partially mitigates this by maintaining solubility, but it does not fully prevent precipitation at physiological duodenal pH.
4.5 Paramagnetic Properties
The Fe3+ center renders ferric ammonium citrate paramagnetic. Ferric ammonium citrate is paramagnetic, producing a high MRI signal intensity by virtue of its spin-lattice (T1) relaxation rate enhancement properties. This property underlies its use as an oral MRI contrast agent (discussed in Section 6.3).
5. Scientific Evidence by Area of Application
5.1 Iron-Deficiency Anemia (IDA): General Population
Evidence level: Moderate — supported by clinical trials, but head-to-head data against ferrous salts show mixed bioavailability.
A randomized controlled clinical study compared the effect of iron amino acid chelated (AACI) preparation versus ferric ammonium citrate (FAC) in the treatment of iron-deficiency anemia. The study was conducted on 160 children aged 5–13 years old proven to have iron deficiency according to WHO 2001 guidelines. Patients were assigned 1:1 to either AACI or FAC, once daily at bedtime, and were followed up for eight weeks.
In some interesting researches, it was found that although the absorption of ferric ammonium citrate (FAC) was significantly lower, still it had an appreciable and adequate iron bioavailability. The relative bioavailability (RBV) of iron in ferric iron salts varies with the composition of the meals and the age of the consumer.
In contrast to these positive findings, a clinical study published in the journal Arzneimittelforschung reached a more critical conclusion regarding bioavailability: trivalent iron in simple compounds like ferric ammonium citrate is so poorly available for intestinal iron absorption in humans that it cannot be used for a fast and reliable oral iron therapy with reasonably low doses as it can be easily practiced with quick-release preparations of ferrous sulfate. This older clinical trial represents an important counterpoint and underscores that the bioavailability evidence for FAC is genuinely mixed.
A separate analysis of comparative iron supplementation data found: data analyzed in 185 patients who received ferric ammonium citrate and folic acid showed significantly improved mean hemoglobin and anemia indices at end of study; however, there was no significant difference between groups when compared to alternative iron formulations, and ferric ammonium citrate was considered a best cost-effective choice for treatment of iron-deficiency anemia.
A study registered with PubMed (PMID 1919803) evaluated "Improvement in iron deficiency anemia through therapy with ferric ammonium citrate and vitamin C and the effects of aerobic exercise", published in Arzneimittelforschung (1984), classified as a clinical trial, indicating FAC has been formally studied in combination with vitamin C for IDA.
5.2 Iron-Deficiency Anemia in Chronic Kidney Disease (CKD)
Evidence level: Strong for ferric citrate formulations in CKD, with regulatory approval — note the overlap and distinction between ferric ammonium citrate and ferric citrate discussed below.
It is important to clarify that most of the strongest recent clinical evidence relates to ferric citrate (a closely related but distinct compound — a coordination complex of iron(III) and citric acid without ammonia) rather than ferric ammonium citrate specifically. However, FAC and ferric citrate share the same iron oxidation state and a closely related mechanism, and FAC's MRI contrast product (FerriSeltz) is distinguished from ferric citrate pharmaceutical products. Ferric ammonium citrate is used in medicine to treat iron-deficiency anemia in humans and is also used as a positive oral contrast agent in magnetic resonance imaging (FerriSeltz®).
Regarding ferric citrate in CKD: a new FDA approval of ferric citrate was based on results from a 24-week, placebo-controlled, phase 3 trial, published in the Journal of the American Society of Nephrology. The trial enrolled 234 adults with stage 3–5 non-dialysis-dependent CKD and iron-deficiency anemia; patients had hemoglobin levels between 9.0 g/dL and 11.5 g/dL and were intolerant to or had an inadequate response to prior treatment with oral iron supplements. Significantly more patients in the ferric citrate arm than the placebo arm had increases in hemoglobin levels of at least 1 g/dL at any point during the trial's 16-week efficacy period — 52.1% (61/117) versus 19.1% (22/115), respectively (P<0.001). Serious adverse events occurred in 12.0% of patients in the ferric citrate arm and 11.2% in the placebo arm.
A phase 2 double-blind, placebo-controlled 12-week trial in 149 CKD patients found: ferric citrate treatment increased mean TSAT from 22% ± 7% to 32% ± 14% and reduced serum phosphate levels from 4.5 ± 0.6 to 3.9 ± 0.6 mg/dL, while placebo exerted no effect.
5.3 Use as an MRI Gastrointestinal Contrast Agent
Evidence level: Moderate — demonstrated in clinical trials, but replaced in many settings by other agents.
Ferric ammonium citrate was investigated and used clinically as an oral gastrointestinal MRI contrast agent beginning in the 1980s. Ferric ammonium citrate produced high signal intensity within the esophagus, stomach, duodenum, and small intestine that aided in the differentiation of the gastrointestinal tract from adjacent tumors, vessels, and viscera. Delineation of the gastrointestinal tract in MRI had previously remained a problem.
A phase III clinical trial of a commercial FAC-based bowel contrast agent, FerriSeltz, enrolled 174 patients: FerriSeltz is a ferric ammonium citrate–based bowel contrast agent formulated as a powder dissolved in 300 ml of water to create a grape-flavored effervescent drink. Groups receiving 600 mg and 1200 mg of ferric ammonium citrate were compared; FerriSeltz was found to brighten the stomach and duodenum, contribute to improvement in diagnostic efficacy, be safe as a bowel contrast agent in abdominal MRI, and be associated with an extremely low incidence of side effects (only mild diarrhea in one of 169 patients).
In a prospective clinical study, FAC significantly (P < 0.001) increased accuracy and specificity for diagnoses involving the stomach and duodenum for both readers and for one reader for the pancreas. The investigators concluded that FAC is helpful in demonstrating and excluding upper gastrointestinal pathology on MRI.
However, a practical limitation was noted: to obtain reasonable contrast enhancement, a relatively high dose of ferric iron is required, and some of this iron is absorbed as it passes down the gastrointestinal tract. Absorption of the iron creates two problems: first, absorption of the iron may cause problems with iron toxicity and iron overload; second, as the iron is absorbed from the gastrointestinal tract, the concentration of the contrast agent decreases and the degree of contrast enhancement is much less in the distal bowel.
5.4 Food Fortification
Evidence level: Established for use; comparative bioavailability versus other fortification forms is variable.
Ferric ammonium citrate is still used in the treatment of anemia, although other iron salts are increasingly preferred; it is also employed as an aid to emulsification in the manufacture of processed foodstuffs, for example, cheese. It is one of the few soluble iron compounds that can be added to dairy products without inducing off-flavors, which gives it a practical advantage in food fortification applications. Japanese food additive standards require an iron content of 16.5%–21.2% in the product used for fortification.
The relative bioavailability of Fe3+ iron salts varies depending on the mean composition and the consumer's age. Studies indicate that ferric ammonium citrate is better absorbed when ingested at modest pharmacological dosages.
5.5 In Vitro and Preclinical Research: P-glycoprotein and Blood-Brain Barrier
Evidence level: Preliminary — in vitro only; no clinical significance established.
Laboratory research has examined the effects of FAC on P-glycoprotein (P-gp), a drug efflux transporter relevant to blood-brain barrier pharmacology: P-gp protein and MDR1 transcript levels were assessed in immortalized human cerebral microvascular endothelial (hCMEC/D3) cells treated with ferric ammonium citrate (FAC; 250 µM, 72 h). FAC treatment significantly reduced P-gp protein (36%) and MDR1 mRNA (16%) levels, with no significant change in rhodamine-123 or [3H]-digoxin accumulation. While P-gp/MDR1 downregulation was associated with elevated ROS and intracellular iron, MDR1 downregulation was not attenuated with the antioxidant N-acetylcysteine nor the iron chelators desferrioxamine and deferiprone, suggesting involvement of a ROS-independent mechanism or incomplete iron chelation. These are cell-culture findings only and have no established clinical significance.
6. Body Systems and Health Areas Associated with Ferric Ammonium Citrate
6.1 Hematopoietic System
The primary therapeutic application is in the hematopoietic system. As a drug, ferric ammonium citrate falls under the category of iron supplements, specifically aimed at replenishing iron stores in the body. The indications include iron-deficiency anemia, chronic kidney disease–related anemia, and anemia due to blood loss or poor absorption. Iron is required for the synthesis of hemoglobin within red blood cells; supplementation with FAC raises hemoglobin and serum ferritin levels, and increases transferrin saturation (TSAT) in iron-deficient individuals.
6.2 Renal System
In patients with chronic kidney disease, closely related ferric citrate compounds (which share the core Fe3+–citrate chemistry of FAC) have a documented dual role: ferric citrate has been reported to have the potential to reduce phosphate and increase iron availability in patients with chronic kidney disease. When used for treatment of patients with non-dialysis-dependent CKD (NDD-CKD), ferric citrate corrects two of the principal metabolic manifestations of CKD: iron-deficiency anemia and relative hyperphosphatemia. This phosphate-binding action results from free ferric iron forming insoluble ferric phosphate complexes in the GI lumen, preventing phosphate absorption.
6.3 Gastrointestinal Tract (Imaging)
As discussed in Section 5.3, ferric ammonium citrate exerts its MRI contrast effect within the GI lumen. Ferric ammonium citrate is one of the proposed paramagnetic, positive GI contrast agents. Paramagnetic materials cause both T1 and T2 shortening; at low concentrations used for bowel opacification, the T1 shortening dominates the signal intensity, resulting in high intensity on T1-weighted, T2-weighted, and gradient echo images.
6.4 Cardiovascular System (Indirect)
Research on ferric citrate hydrate in patients with chronic heart failure and co-existing iron-deficiency anemia found: ferric citrate hydrate significantly increased hemoglobin, serum iron, transferrin saturation, and ferritin levels, and decreased atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. Improvement in iron metabolism and anemia due to iron supplementation with ferric citrate hydrate led to improvement in heart failure biomarkers. These findings are for ferric citrate hydrate, and clinical extrapolation to ferric ammonium citrate specifically should be made with caution.
6.5 Photographic/Artistic Applications (Non-Medical)
The cyanotype is a slow-reacting, photographic printing formulation sensitive to near-ultraviolet and blue light (300–400 nm). It produces a monochrome, blue-coloured print and is often used for art and reprography in the form of blueprints. The process uses two chemicals — ferric ammonium citrate or ferric ammonium oxalate, and potassium ferricyanide — and only water to develop and fix. Announced in 1842, it is still in use.
7. Dosage Forms and Dosages Reported in Studies
7.1 Pharmaceutical Preparations
Ferric ammonium citrate has been formulated as:
- Oral syrups and liquid elixirs (the classical preparation for iron tonics)
- Powder for oral solution (e.g., FerriSeltz for MRI contrast use)
- Tablets (ferric citrate, related compound)
- Food fortification powders and granules
7.2 Dosages Used in Clinical Studies
- Iron-deficiency anemia in children (randomized clinical trial, PMC 2024): Patients were assigned to FAC once daily at bedtime and followed up for eight weeks. The specific elemental iron dose per administration was not stated in the available abstract.
- MRI contrast (Phase III clinical trial, FerriSeltz, 174 patients): Groups receiving 600 mg and 1200 mg of ferric ammonium citrate were evaluated for abdominal MRI contrast.
- Ferric citrate for CKD (Phase 3 trial, 234 patients): The starting dose in both phase 2 and phase 3 trials was three 1-gram (210 mg elemental iron) tablets per day with food, which could be increased to a maximum of 12 tablets per day.
- Ferric citrate FDA-approved starting dose: The recommended starting dose is 2 tablets orally 3 times per day with meals.
- Dosage range in FDA trial program: Across trials, dosage regimens ranged from 210 mg to 2,520 mg of ferric iron per day.
8. Safety Considerations and Drug Interactions
8.1 Iron Overload
Patients with iron overload syndromes (e.g., hemochromatosis) are contraindicated to take ferric citrate/ferric ammonium citrate compounds, as the iron absorption may lead to excessive elevation in iron stores. There was one case of iron overload as confirmed by liver biopsy in a patient administered IV iron and ferric citrate concurrently; otherwise analyses of adverse event data did not indicate a higher incidence of adverse events suggestive of iron overload in the ferric citrate arm. Because iron is absorbed from ferric citrate, iron absorption leading to iron deposition in tissues and iron overload is a potential risk.
8.2 Gastrointestinal Adverse Effects
In clinical trials, adverse events reported in more than 5% of patients treated with ferric citrate at a rate similar to the control group included diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%), and cough (6%). When used for treatment of NDD-CKD patients, ferric citrate contributes to gastrointestinal adverse events at higher rates than placebo. The high water solubility of FAC — while beneficial for bioavailability — may explain why GI tolerability is generally considered favorable compared with some other iron salts, though it is not uniformly well tolerated.
8.3 Stool Discoloration
Ferric citrate is associated with discolored feces (dark stools) related to the iron content, but this staining is not clinically relevant and does not affect laboratory tests for occult bleeding, which detect heme rather than non-heme iron in the stool.
8.4 Pediatric Overdose Risk
Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. An overdose of iron in pregnant women may carry a risk of spontaneous abortion, gestational diabetes, and fetal malformation.
8.5 Drug Interactions
Because ferric ammonium citrate delivers iron in ionic form, it is subject to the same class of drug interactions documented for oral iron in general:
- Concurrent ingestion of oral iron causes marked decrease in the bioavailability of a number of drugs due to the formation of iron-drug complexes (chelation or binding of iron by the second drug).
- Examples of affected drugs include: quinolone or tetracycline antibiotics, bisphosphonates, angiotensin-converting enzyme inhibitors, folic acid, methyldopa, levodopa, carbidopa, levothyroxine, and mycophenolate.
- Antacids and proton pump inhibitors, commonly used to treat acid reflux and peptic ulcers, can reduce stomach acidity, thereby hindering the conversion of ferric iron to its more absorbable ferrous form. It is therefore advisable to take ferric ammonium citrate at least 1 to 2 hours before or after such medications.
- Certain antibiotics such as tetracyclines and fluoroquinolones can form complexes with iron, reducing the absorption of both the antibiotic and the iron supplement; spacing the administration of these drugs by at least 2 to 4 hours is recommended.
- High doses of calcium supplements can also interfere with iron absorption and should be taken separately from ferric ammonium citrate.
8.6 Monitoring Parameters
Iron overload risk requires monitoring of ferritin and transferrin saturation (TSAT); patients receiving concurrent IV iron may require a reduction in dose or discontinuation of the IV iron.
8.7 Populations with Specific Considerations
Patients with inflammatory bowel disease or active, symptomatic gastrointestinal bleeding were excluded from clinical trials of ferric citrate-class compounds. Ferric ammonium citrate / ferric citrate should not be used in individuals with an iron overload disorder such as hemochromatosis.
9. Other Industrial and Scientific Applications
Beyond medicine and food science, ferric ammonium citrate has several additional documented applications:
- Cyanotype photography and blueprinting: As described above, FAC remains an active reagent in the cyanotype photographic process. The cyanotype process uses light-sensitive iron salts produced by brushing solutions of ferric ammonium citrate and potassium ferricyanide onto paper, which is then dried in the dark; cyanotypes were not widely used until 1880, when they became popular because they required only water for fixing the image.
- Microbiology: Ammonium ferric citrate is used in Kligler iron deeps to determine hydrogen sulfide production in microbial metabolism.
- Water purification: It is used in water purification processes by aiding coagulation and precipitation of suspended particles.
- Nanomaterial synthesis: Ammonium iron(III) citrate can be used as a reagent and iron precursor in several organic reactions and Fe3O4-based nanomaterial preparation; it can be prepared by treating Fe(OH)3 with citric acid and NH4OH in various ratios.
- Animal feed: It is used as an animal feed additive.
10. Evidence Summary and Characterization
The body of evidence supporting ferric ammonium citrate can be summarized as follows:
- Iron-deficiency anemia: FAC has been used clinically for over a century and is supported by multiple clinical trials, though evidence is mixed. Its bioavailability is lower than that of ferrous sulfate in several comparative studies, but it demonstrates appreciable and adequate iron bioavailability — especially at lower pharmacological doses and when coadministered with vitamin C. The strongest modern clinical trial data (Phase 3, double-blind, placebo-controlled) is for closely related ferric citrate in CKD populations, with regulatory approval from the FDA.
- MRI contrast agent: FAC as FerriSeltz has Phase III trial support for GI opacification, with good safety in studied populations. Practical limitations include iron absorption from high-dose use and diminishing contrast in the distal bowel.
- Blood-brain barrier / P-gp interactions: Preliminary, in vitro only; no clinical significance established.
- Food fortification: Well-established functional use, particularly favored for dairy products due to off-flavor neutrality. Regulatory approval in many jurisdictions.
References
Go back